Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 12/20 | 0.35 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.34 |
| ▸ | XIAP | P98170 | 4/20 | 0.33 |
| ▸ | BIRC3 | Q13489 | 4/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 4/20 | 0.33 |
| ▸ | BIRC8 | Q96P09 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24664618 | 1.00 | CFD (0.35) | CFDPSMB9XIAPBIRC3BIRC2 | |
| SCHEMBL24665687 | 0.88 | CFD (0.36) | CFDPSMB9DRD2 | |
| SCHEMBL29230886 | 0.88 | CFD (0.36) | CFDPSMB9DRD2 | |
| SCHEMBL29820279 | 0.88 | GPR88 (0.36) | CFDPSMB9ITGA4 | |
| SCHEMBL24664659 | 0.88 | GPR88 (0.36) | CFDPSMB9ITGA4 | |
| SCHEMBL24666300 | 0.87 | CFD (0.35) | CFDPSMB9XIAPBIRC3BIRC2 | |
| SCHEMBL29230621 | 0.87 | CFD (0.35) | CFDPSMB9XIAPBIRC3BIRC2 | |
| SCHEMBL24666481 | 0.87 | CFD (0.37) | CFDPSMB9DRD2 | |
| SCHEMBL29820240 | 0.87 | CFD (0.37) | CFDPSMB9DRD2 | |
| SCHEMBL26833084 | 0.86 | CFD (0.41) | CFDXIAPBIRC3BIRC2BIRC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308095-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022198196-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |